tradingkey.logo

STAAR Surgical Co

STAA
View Detailed Chart
17.580USD
+0.510+2.99%
Close 02/06, 16:00ETQuotes delayed by 15 min
867.64MMarket Cap
LossP/E TTM

STAAR Surgical Co

17.580
+0.510+2.99%
Intraday
1m
30m
1h
D
W
M
D

Today

+2.99%

5 Days

-7.23%

1 Month

-21.11%

6 Months

-34.65%

Year to Date

-23.86%

1 Year

-23.00%

View Detailed Chart

TradingKey Stock Score of STAAR Surgical Co

Currency: USD Updated: 2026-02-06

Key Insights

STAAR Surgical Co's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 68 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 23.62.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

STAAR Surgical Co's Score

Industry at a Glance

Industry Ranking
68 / 205
Overall Ranking
179 / 4521
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

STAAR Surgical Co Highlights

StrengthsRisks
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -9.00, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 52.84M shares, decreasing 21.22% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 212.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.61.

Analyst Rating

Based on 11 analysts
Hold
Current Rating
23.625
Target Price
+38.40%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

STAAR Surgical Co News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

STAAR Surgical Co Info

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
Ticker SymbolSTAA
CompanySTAAR Surgical Co
CEOFarrell (Stephen C)
Websitehttps://www.staar.com/
KeyAI